NEWS
Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting
Candel Therapeutics (Nasdaq: CADL), a clinical-stage biopharmaceutical company developing multimodal biological immunotherapies for cancer, announced its upcoming presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting. The event will take place from November 6-10, 2024, in Houston, Texas, and virtually.
The company will present a poster titled 'Therapeutic potential of CAN-3110 in Ras-Raf pathway altered melanoma'. Dr. Anne Diers, Senior Director of Research at Candel Therapeutics, will present the abstract numbered 995 on Friday, November 8, 2024, in the Exhibit Halls A and B of the George R. Brown Convention Center.
Additional details from the presentation will be made available on Candel's website following the event.
The company will present a poster titled 'Therapeutic potential of CAN-3110 in Ras-Raf pathway altered melanoma'. Dr. Anne Diers, Senior Director of Research at Candel Therapeutics, will present the abstract numbered 995 on Friday, November 8, 2024, in the Exhibit Halls A and B of the George R. Brown Convention Center.
Additional details from the presentation will be made available on Candel's website following the event.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2579Followers
107Following
28KVisitors
Follow